SCHEMBL31119461

CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)N)C(C)C)C(=O)N[C@@H](CO)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)O

nearest known ligand 0.56

Predicted protein targets (top 5)

	gene	UniProt	supporting neighbours	confidence
▸	C5AR1	P21730	1/20	0.56

▸	CALCA	P06881	2/20	0.55

▸	GLP1R	P43220	14/20	0.55

▸	GIPR	P48546	14/20	0.55

▸	CXCR4	P61073	2/20	0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL31119468	1.00	C5AR1 (0.56)	C5AR1CALCAGLP1RGIPRCXCR4
SCHEMBL30665211	0.96	C5AR1 (0.59)	C5AR1CALCAGLP1RGIPRCXCR4
SCHEMBL29763090	0.95	GLP1R (0.61)	C5AR1CALCAGLP1RGIPRCXCR4
SCHEMBL29762984	0.95	GLP1R (0.61)	C5AR1CALCAGLP1RGIPRCXCR4
SCHEMBL30490787	0.92	CALCA (0.57)	CALCAGLP1RGIPR
SCHEMBL31058456	0.90	C5AR1 (0.56)	C5AR1GLP1RGIPR
SCHEMBL31058453	0.90	GLP1R (0.55)	C5AR1GLP1RGIPR
SCHEMBL29880262	0.89	PTH1R (0.63)	CALCAGLP1RGIPRCXCR4
SCHEMBL30467090	0.88	CAPN1 (0.52)	CXCR4
SCHEMBL31703183	0.88	GLP1R (0.69)	GLP1RGIPR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20240299499-A1	Therapeutic Peptide Formulations	ELI LILLY AND COMPANY	2024-09-12	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20240299499-A1	Therapeutic Peptide Formulations	GLP1R, GIPR, IAPP	C5AR1 1190/4885CALCA 85/4885GLP1R 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.